Adam M. Koppel rejoined Bain Capital in 2016 as Managing Director of Bain Capital Life
Sciences. He initially joined Bain Capital Public Equity in 2003 where he worked as a leader
within the healthcare sector until 2014. From 2014 to 2016, Dr. Koppel was EVP of Corporate
Development and Chief Strategy Officer at Biogen. He sits on the Board of Directors of
AavantiBio, Aptinyx (NASD: APTX), Cerevel Therapeutics (NASD: CERE), Dicerna
Pharmaceuticals (NASD: DRNA), Foghorn Therapeutics (NASD: FHTX), Solid Biosciences
(NASD: SLDB) and ViaCyte.
Prior to initially joining Bain Capital in 2003, Dr. Koppel was an Associate Principal at McKinsey
& Co in New Jersey where he served a variety of healthcare companies.
Dr. Koppel sits on the Newton-Wellesley Hospital Board of Trustees, the Boston Museum of
Science Board of Trustees, the Partners Healthcare Innovation Advisory Board, and the Society
for Neuroscience Investment Committee. In addition, he sits on the Gann Academy Board of
Trustees and CJP’s Budget and Administration Committee. He previously sat on the Board of
Temple Beth Elohim in Wellesley MA, from 2014-2017.
Dr. Koppel received an MD and PhD in Neuroscience from the University of Pennsylvania
School of Medicine. He also received an MBA from The Wharton School at the University of
Pennsylvania, where he was a Palmer Scholar. He graduated magna cum laude from Harvard
University with an AB and AM in History and Science.
